Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors

QR Code

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Zheng-Hang Wang, Lin Shen
Format:	article
Langue:	EN
Publié:	KeAi Communications Co., Ltd. 2018
Sujets:	Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/91ffb87ed5424e9fa51855f3125993c1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Managing cardiotoxicity associated with immune checkpoint inhibitors
par: Sireesha Upadhrasta, et autres
Publié: (2019)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
par: Xiaoyin Bai, et autres
Publié: (2021)

Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
par: Marina A. Lyadova, et autres
Publié: (2021)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
par: Zoe Apalla, et autres
Publié: (2021)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
par: Rilan Bai, et autres
Publié: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
par: Kennedy Yao Yi Ng, et autres
Publié: (2021)

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
par: Despina Michailidou, et autres
Publié: (2021)

Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development
par: Ke Cheng, et autres
Publié: (2021)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
par: Tomas G Neilan, et autres
Publié: (2021)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
par: Zhenghang Wang, et autres
Publié: (2021)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
par: Ying Jing, et autres
Publié: (2020)

Correction: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
Publié: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
par: Di Wang, et autres
Publié: (2021)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
par: Nuttapong Ngamphaiboon, et autres
Publié: (2021)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
par: Pan Shen, et autres
Publié: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
par: Qi J, et autres
Publié: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
par: Can Öztürk, et autres
Publié: (2021)

Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
par: Rosaria De Filippi, et autres
Publié: (2021)

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
par: Paolo Antonio Ascierto, et autres
Publié: (2021)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
par: Yan‐Xing Chen, et autres
Publié: (2021)

Correction: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study
Publié: (2021)

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA
par: Kun-Hsing Yu, et autres
Publié: (2021)

Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types
par: Feicheng Wang, et autres
Publié: (2021)

Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database
par: Yifan Zeng, et autres
Publié: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
par: Zou W, et autres
Publié: (2021)

The roles of exosomal immune checkpoint proteins in tumors
par: Cheng Xing, et autres
Publié: (2021)

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
par: Susan M. O’Brien, et autres
Publié: (2021)

Indicators of responsiveness to immune checkpoint inhibitors
par: Bradley D. Shields, et autres
Publié: (2017)

A Deep Learning-Based Text Classification of Adverse Nursing Events
par: Wenjing Lu, et autres
Publié: (2021)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
par: Xiujing He, et autres
Publié: (2021)

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
par: Theresa L Walunas, et autres
Publié: (2021)

The Mediating Processes between Depression and Cardiac Adverse Events
par: R Bagherian,, et autres
Publié: (2011)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
par: Kyoichi Kaira, et autres
Publié: (2021)

Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
par: Shinsuke Suzuki, et autres
Publié: (2021)

Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age
par: Raffaella Calabretta, et autres
Publié: (2021)

Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer
par: Zhihao Lu, et autres
Publié: (2021)

A decade of immune-checkpoint inhibitors in cancer therapy
par: Caroline Robert
Publié: (2020)

Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency
par: Katsunori Manaka, et autres
Publié: (2021)

Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trial
par: Qinwei Fu, et autres
Publié: (2021)

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
par: Pottayil G. Sasikumar, et autres
Publié: (2021)